- Researchers at the University of Illinois Chicago have developed a novel cancer treatment that utilizes bacteria found within tumors to target how cancer cells produce energy, rather than directly attacking the cells themselves.
- This innovative therapy employs a newly designed peptide, aurB, which infiltrates tumor cell mitochondria to inhibit ATP synthase, a critical enzyme for energy production, effectively starving the cancer cells.
- According to SciTechDaily, the aurB peptide, derived from a bacterial protein called auracyanin, demonstrated significant tumor growth inhibition in preclinical animal models of prostate cancer, especially when combined with radiation therapy.
- The approach was effective even in p53-inactive and hormone therapy-resistant prostate cancer models, offering hope for difficult-to-treat cases.
- As reported by the University of Illinois Cancer Center, Dr. Tohru Yamada, a senior author on the study, emphasized that "The mitochondria are very important for a cell to survive; they are the energy factories".
- The patented aurB peptide is now poised for progression into clinical trials, marking a significant step towards new treatments for cancers with limited therapeutic options.
UIC's New Cancer Energy Attack
University of Illinois Chicago researchers have developed a groundbreaking cancer treatment that starves tumor cells by inhibiting their energy production with a bacteria-derived peptide called aurB. This innovative therapy demonstrated significant tumor growth inhibition in preclinical prostate cancer models, including resistant types, and is now poised for human clinical trials.
Reporting Sources
6
Report an issue with this article
Please sign in to report issues with this article.
Live discussion about this article
Comments
Comments are disabled for this article.
